Generic pharmaceutical producers to benefit from new policies


The Pakatan Harapan government, in its election manifesto, aimed to elevate health expenditure from 4% of GDP to 6%-7% of GDP.

PETALING JAYA: Generic pharmaceutical producers are expected to be best poised to benefit from the deliberated policies relating to the healthcare sector, according to Affin Hwang Capital Research.

However, the research house said organic recovery and the sheer size of an expanded healthcare expenditure should well catalyse the entire sector.

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Wall St set for higher open as chip stocks bounce back after selloff
Malaysia's video gaming industry projected to hit US$649mil revenue in 2024
Farhash ceases to be HeiTech Padu’s substantial shareholder
MATRADE formulating strategies to address geopolitical challenges
Trading in Awanbiru shares to be suspended april 26
Ringgit continues to close higher against US dollar
RHB expands sustainable financial services target to RM50bil by 2026
Astaka awards Kimlun with RM150mil construction contract
Yinson GreenTech, Eastern Pacific Shipping team up for greener shipping industry
Affin launches cashless initiative for Lembaga Muzium Negeri Terengganu

Others Also Read